Lexicon Pharmaceuticals: from Discovery to Development




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Lexicon Pharmaceuticals: from Discovery to Development
Released on: June 01, 2007. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this exclusive interview, Fintan Walton talks to Arthur Sands, President and Chief Executive Officer of Lexicon Pharmaceuticals, about the company's recent name change from Lexicon Genetics and how this signals a shift from drug discovery to clinical development.
  • Summary
  • Participants
  • Company
In this exclusive interview, Fintan Walton talks to Arthur Sands, President and Chief Executive Officer of Lexicon Pharmaceuticals, about the company's recent name change from Lexicon Genetics and how this signals a shift from drug discovery to clinical development. Dr Sands discusses Lexicon's deals with Genentech and Bristol-Myers Squibb (BMS), and the ways in which the company captures long-term value in these partnerships. Also detailed is the science behind Lexicon's programmes and the strategy going forward as the company moves its first products into clinical development, including the goal of advancing ten drug candidates into human clinical trials by the end of 2010.
Dr Arthur Sands co-founded Lexicon Pharmaceuticals and has been President and Chief Executive Officer and a Director since September 1995. At Lexicon, Dr Sands pioneered the development of large-scale gene knockout technology for use in drug discovery. Before founding Lexicon, Dr Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. Dr Sands is a member of the Board of Directors of the Texas Institute for Genomic Medicine. He received his BA in economics and political science from Yale University and his MD and PhD from Baylor College of Medicine.
Lexicon Pharmaceuticals